well galette, first of all as a disclaimer, anything I post comes outa my butt hole, IMO dont follow any of it!
having said that, with this type of biotech reverse merging into a current reporting, debt free shell, and the merging company being capably managed, and with cancer treatment in tow, and very low float, and a Trump FDA nod,
investors will speculate above and beyond hard number valuations.
AND NO TICKY, NO WASHY! (GET SHARES IMO)